BrigitteCWidemannMD

Clinical Trials

• Study of Plexiform Neurofibromas in Neurofibromatosis Type 1 Start of enrollment: 2001 May 18

  Completed

• Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors Start of enrollment: 2001 Feb 15

  Completed

  Phase 1

• Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate Start of enrollment: 1993 Nov 01

  Completed

  Not Applicable

• Tipifarnib in Treating Young Patients With Refractory Leukemia Start of enrollment: 2001 Jun 01

  Completed

  Phase 1

• Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas Start of enrollment: 2002 Dec 01

  Completed

  Phase 1

• Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Start of enrollment: 2004 Jul 21

  Completed

  Phase 2

• PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Start of enrollment: 2005 Sep 01

  Completed

  Phase 1

• Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2005 Dec 01

  Completed

  Phase 2

• AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia Start of enrollment: 2006 May 01

  Completed

  Phase 1

• Ixabepilone in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2006 Apr 01

  Completed

  Phase 2

• Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development Start of enrollment: 2004 Sep 07

  Completed

• A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias Start of enrollment: 2006 May 01
• Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer Start of enrollment: 2007 Jul 20

  Completed

  Phase 1, Phase 2

• A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Start of enrollment: 2008 Mar 01
• A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas Start of enrollment: 2008 May 01
• Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Start of enrollment: 2008 Jul 08

  Completed

  Phase 1

• A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Start of enrollment: 2009 Jul 01

  Completed

  Phase 2

• Natural History Study of Patients With Neurofibromatosis Type I Start of enrollment: 2008 Feb 25

  Active, not recruiting

• Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Start of enrollment: 2010 Jul 10

  Completed

  Phase 2

• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors Start of enrollment: 2010 Dec 03

  Completed

  Phase 1

• AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Start of enrollment: 2011 Sep 21

  Active, not recruiting

  Phase 1, Phase 2

• Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia Start of enrollment: 2006 May 30

  Completed

  Phase 1, Phase 2

• Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Start of enrollment: 2011 Dec 01

  Completed

  Phase 1

• Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma Start of enrollment: 2012 May 10

  Terminated

  Phase 1, Phase 2

• Natural History Study of Children and Adults With Medullary Thyroid Cancer Start of enrollment: 2012 Jul 30

  Recruiting

• SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2012 Sep 01

  Completed

  Phase 2

• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14

  Completed

  Phase 1

• Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Start of enrollment: 2013 May 15

  Completed

  Phase 2

• SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Start of enrollment: 2013 Dec 01

  Completed

  Phase 1, Phase 2

• Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Start of enrollment: 2013 Dec 14

  Completed

  Phase 2

• MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01

  Completed

  Phase 2

• Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Start of enrollment: 2014 Jun 01

  Completed

  Phase 2

• VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01

  Completed

  Phase 1

• Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Start of enrollment: 2014 Dec 08

  Completed

  Phase 1

• A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11

  Completed

  Phase 1

• http://clinicaltrials.gov/ct2/show/NCT02644512
• Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Start of enrollment: 2017 Aug 26

  Completed

  Phase 2

• Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Start of enrollment: 2017 Apr 07

  Withdrawn

  Phase 2

• SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2019 Oct 02

  Completed

  Phase 2

• SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients Start of enrollment: 2021 Jan 05

  Active, not recruiting

  Phase 1, Phase 2

• Join now to see all